Abcam, ab247710, Anti-Myosin light chain 3 antibody [EPR4160] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal MYL3 antibody. Carrier free. Suitable for IHC-P, WB and reacts with Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR4160,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:IHC-P, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab247710 is the carrier-free version of
ab108923
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Myosin light chain 3 (MLC3) also known as myosin regulatory light chain 3 is a part of the myosin protein complex. It plays a major role in muscle contraction by regulating the ATPase activity of myosin heads. MLC3 is encoded by the MYL3 gene and has a molecular mass of approximately 18kDa. It is expressed mainly in cardiac and skeletal muscle tissues. By interacting with myosin heavy chains MLC3 contributes to the force-generating capacity of muscles.
Biological function summary
MLC3 functions as an essential component of the myosin light chain complex. This complex regulates contractile activity in muscle cells by modulating the interaction between actin and myosin chains. MLC3 activates the mechanical movement of myosin chains impacting cardiac and skeletal muscle contraction. When activated it affects the speed and strength of muscle contraction and it also has a role in muscle differentiation and development.
Pathways
MLC3 is an integral part of the muscle contraction pathway. It interacts with proteins such as tropomyosin and troponin which are important for the regulation of muscle contraction. Additionally MLC3 participates in the calcium signaling pathway which is pivotal for contraction processes in muscles. This interaction helps to control the cytosolic calcium concentration a critical factor in muscle contraction dynamics.
MLC3 has connections to cardiomyopathy and hypertrophic conditions. Mutations or dysregulation of MYL3 can lead to cardiac hypertrophy a disease where the heart muscle thickens abnormally. MLC3's interaction with troponin and other myosin chains can exacerbate cardiac conditions when these pathways are disrupted. Studies have linked deficiencies in MLC3 to improper muscle development which may underline some muscle myopathies.